Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.66 |
| ▸ | KDR | P35968 | 8/20 | 0.64 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19100193 | 0.90 | EGFR (0.68) | EGFRERBB2KDR | |
| Maleic Acid SCHEMBL20637511 | 0.87 | EGFR (0.65) | EGFRERBB2KDRERBB4 | |
| SCHEMBL19639014 | 0.86 | EGFR (0.87) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL30101593 | 0.86 | EGFR (0.87) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL5648037 | 0.85 | EGFR (0.69) | EGFRERBB2KDRJAK3ERBB4 | |
| SCHEMBL5648049 | 0.85 | EGFR (0.69) | EGFRERBB2KDRJAK3ERBB4 | |
| SCHEMBL26930728 | 0.84 | EGFR (0.78) | EGFRERBB2KDRJAK3ERBB4 | |
| SCHEMBL2131031 | 0.82 | EGFR (0.87) | EGFRERBB2KDRJAK3ERBB4 | |
| SCHEMBL2131022 | 0.82 | EGFR (0.87) | EGFRERBB2KDRJAK3ERBB4 | |
| SCHEMBL19124461 | 0.81 | EGFR (0.63) | EGFRERBB2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957237-B2 | Crystal form of neptinib di-p-methylbenzenesulfonate, preparation method thereof, and pharmaceutical composition containing same | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2018-05-01 | — | — | US | disclosed |
| US-20170342037-A1 | A CRYSTAL FORM OF NEPTINIB di-P-METHYLBENZENESULFONATE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342037-A1 | A CRYSTAL FORM OF NEPTINIB di-P-METHYLBENZENESULFONATE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ABL1, NEK5, CYP2D6 | EGFR 252/4885ERBB2 874/4885KDR 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.